Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

Patent metadata

Field	Value
Publication number	US-12371747-B2
Application number	US-202217681435-A
Country	US
Kind code	B2
Filing date	Feb 25, 2022
Priority date	Jan 12, 2012
Publication date	Jul 29, 2025
Grant date	Jul 29, 2025

Abstract

The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain.

First claim

What is claimed is:

1. A method of reducing an inhibitory Factor VIII (FVIII) immune response in a subject who has hemophilia A, comprising administering to the subject a chimeric polypeptide comprising a FVIII polypeptide and an Fc, wherein the Fc comprises an amino acid sequence at least 95% identical to amino acids 1458 to 1684 of SEQ ID NO: 2, wherein the subject has developed an inhibitory FVIII immune response to a FVIII protein, and wherein the immune response comprises inhibitory anti-FVIII antibodies, wherein the subject is identified to have one or more characteristics selected from the group consisting of:
(a) is receiving interferon therapy;
(b) is receiving anti-viral therapy;
(c) has a genetic mutation in a gene other than the gene encoding FVIII which is linked with an increased risk of developing an inhibitory immune response; and
(d) any combination thereof.

2. The method of claim 1 , wherein the subject has a relative who has previously developed an inhibitory FVIII immune response.

3. The method of claim 1 , wherein the FVIII polypeptide comprises an amino acid sequence at least 90% identical to amino acids 20 to 1457 of SEQ ID NO: 2.

4. The method of claim 1 , further comprising measuring the level of the inhibitory FVIII immune response before the administration of the chimeric polypeptide.

5. The method of claim 4 , further comprising comparing the level of the inhibitory FVIII immune response after the administration of the chimeric polypeptide with the level of the inhibitory FVIII immune response before the administration of the chimeric polypeptide.

6. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies prior to the administration of the chimeric polypeptide is at least about 0.6 Bethesda Units (BU).

7. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies prior to the administration of the chimeric polypeptide is at least about 1.0 BU.

8. The method of claim 1 , wherein the concentration of the inhibitory antibodies prior to the administration is at least about 5.0 Bethesda Units (BU).

9. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies after the administration of the chimeric polypeptide is less than about 1.0 BU.

10. The method of claim 1 , wherein the concentration of the inhibitory anti-FVIII antibodies after the administration of the chimeric polypeptide is less than about 0.6 BU.

11. The method of claim 1 , wherein the subject has one or more of:
(i) a genetic polymorphism associated with increased TNF-α;
(ii) a genetic polymorphism associated with increased IL-10;
(iii) a genetic polymorphism associated with decreased CTLA-4; and
(iv) a mutation in DR15 or DQB0602 MHC Class II molecules.

12. The method of claim 1 , wherein the chimeric polypeptide comprises a linker between the FVIII polypeptide and the Fc.

13. The method of claim 1 , wherein the chimeric polypeptide comprises an amino acid sequence identical to amino acids 1458 to 1683 of SEQ ID NO: 2.

14. The method of claim 1 , wherein the FVIII polypeptide comprises an amino acid sequence identical to amino acids 20 to 1457 of SEQ ID NO: 2.

15. The method of claim 1 , wherein the chimeric polypeptide is in the form of a hybrid comprising a second polypeptide associated with the chimeric polypeptide via a disulfide bond, wherein the second polypeptide comprises a second Fc portion, and wherein the second Fc portion comprises an amino acid sequence at least 95% identical to amino acids 21 to 247 of SEQ ID NO: 4.

16. The method of claim 1 , wherein the subject is a child less than twelve years old.

17. The method of claim 1 , wherein the subject is an adult.

Assignees

• Bioverativ Therapeutics Inc
• Puget Sound Blood Center

Inventors

• Jiang Haiyan
• Liu Tongyao
• Krishnamoorthy Sriram
• Josephson Neil
• Pierce Glenn

Classifications

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• A61K47/6815

  Enzymes · CPC title

• A61K47/6811

  the drug being a protein or peptide, e.g. transferrin or bleomycin · CPC title

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• C07K14/755

  Factors VIII {, e.g. factor VIII C (AHF), factor VIII Ag (VWF)} · CPC title